Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Eli Lilly buys Sigilon for US$126ps which traded at $0.33ps

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 03, 2023 6:58pm

136 Views

Post# 35668004

RE:RE:RE:Eli Lilly buys Sigilon for US$126ps which traded at $0.33ps

Big Pharma is facing a looming patent cliff and is seeking to fill its therapeutic product pipleline BUT is having to move further up-stream in the product development process in order to obtain biological assets that are experiecing favorable treatment by the Inflation Reduction Act (IRA) as already outlined in earlier posts.

So what some may consider to be an exception, the kind of premium paid for Sigilon Therapeutics Inc and other development biopharma stocks is now expected to become the norm ... particularly for late stage P3 development biopharma companies like ONCY.

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?